SYNACT Stock Overview
A clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
SynAct Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 15.33 |
| 52 Week High | SEK 19.69 |
| 52 Week Low | SEK 6.55 |
| Beta | 0.81 |
| 1 Month Change | -14.12% |
| 3 Month Change | 68.46% |
| 1 Year Change | 123.80% |
| 3 Year Change | -80.37% |
| 5 Year Change | 92.59% |
| Change since IPO | 194.81% |
Recent News & Updates
Recent updates
We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully
Sep 18
Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation
Sep 04Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?
Jan 18Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation
Sep 03SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans
Apr 07Shareholder Returns
| SYNACT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.5% | 0.2% | -1.4% |
| 1Y | 123.8% | 1.1% | 2.0% |
Return vs Industry: SYNACT exceeded the Swedish Biotechs industry which returned 1.1% over the past year.
Return vs Market: SYNACT exceeded the Swedish Market which returned 2% over the past year.
Price Volatility
| SYNACT volatility | |
|---|---|
| SYNACT Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SYNACT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: SYNACT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 6 | Jeppe Ovlesen | synactpharma.com |
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.
SynAct Pharma AB Fundamentals Summary
| SYNACT fundamental statistics | |
|---|---|
| Market cap | SEK 751.31m |
| Earnings (TTM) | -SEK 82.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.1x
P/E RatioIs SYNACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNACT income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 82.40m |
| Earnings | -SEK 82.40m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 10, 2025
| Earnings per share (EPS) | -1.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SYNACT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 11:14 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SynAct Pharma AB is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrik Ling | DNB Markets |
| Carl Ramanius | Redeye |